A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

NCT03412006 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Kidney Disease

Interventions

DRUG: Fulacimstat (BAY1142524)
DRUG: Placebo

Sponsor

Bayer